Lattice Advances Low Power FPGA Leadership with New Small and Mid-range FPGA Offerings
10.12.2024 19:00:00 CET | Business Wire | Press release
‒ Introduces Lattice Nexus 2 next-gen small FPGA platform, extends mid-range portfolio with Lattice Avant 30 and Avant 50 devices, and enhances capabilities of application-specific solution stacks and design software tools ‒
Today, at Lattice Developers Conference 2024, Lattice Semiconductor (NASDAQ: LSCC) expanded its edge to cloud FPGA innovation leadership with the launch of exciting new hardware and software solutions. The new Lattice Nexus™ 2 next-gen small FPGA platform and the first device family based on the platform, Lattice Certus™-N2 general purpose FPGAs, offer advanced connectivity, optimized power and performance, and class-leading security. Lattice also announced new mid-range FPGA device capacity options – Lattice Avant™ 30 and Avant™ 50 – and new versions of Lattice design software tools and application-specific solution stacks to help accelerate customer time-to-market.
“At Lattice, we are proud to lead technological advancements in low power, small form factor FPGAs, ensuring our customers have the optimal devices, tools, and solutions to design groundbreaking applications that are power efficient, fast, and secure,” said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. “From the edge to the cloud across a variety of industries, FPGAs stand at the forefront of innovation, and we’re committed to delivering versatile and robust small and mid-range FPGA solutions that enable our customers and partners to unlock their full potential.”
Advancing Small FPGA Innovation
The new Lattice Nexus 2 small FPGA platform combines connectivity advancements, power and performance optimizations, and leading security and reliability capabilities to meet the growing demand for edge applications requiring efficient processing, bridging, and control capabilities.
Built on the proven 16 nm FinFET TSMC process technology, Lattice Nexus 2 continues company’s low power, small FPGA leadership equipping customers with
-
Power Efficiency
- Up to 3X lower power than similar class competitive devices, enabling power and thermal design efficiencies, improved operating costs, and enhanced reliability.
- Up to 10X energy efficient edge sensor monitoring than similar class competitive devices.
-
Performance
- Up to 3.2X faster MIPI speed than similar class competitive devices for faster connectivity and data transfer.
- Up to 10X faster configuration time than similar class competitive devices enhancing overall efficiency, fault tolerance, and security in safety-critical applications.
-
Form Factor
- Up to 5X smaller size than similar class competitive devices, enabling simplified, efficient system designs.
-
Connectivity
- Combines multi-protocol 16G SERDES with PCIe® Gen 4 controller, high performance I/O, high speed LPDDR4 memory interface support, and industry-leading MIPI D & C-PHY up to 7.98 Gbps.
-
Security
- Industry-leading security with 256-bit AES-GCM and SHA3-512; compliant with FIPS 140-3 level 2 standards.
- Crypto agility, post-quantum ready, and anti-temper protection.
- Integrated flash enabling faster and more secure configuration.
- End user options for customers’ data-in-motion security needs.
The Lattice Nexus 2 platform is architected for scalability that will enable the rapid development of multiple new device families, starting today with the launch of the Lattice Certus™-N2 general purpose FPGA family. Lattice Certus-N2 FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.
Extending Mid-Range FPGA Portfolio
Built on the award-winning Lattice Avant platform, the Avant 30 and Avant 50 offers new capacity options for customers to enable edge optimized and advanced connectivity applications development. These devices provide customers more options for connectivity, functional capacity, and features.
Expanded Solution Stacks
Lattice announced new versions of Lattice Radiant™ and Lattice Propel™ software tools that support the new Lattice Nexus 2 FPGA platform, Lattice Certus-N2 FPGA family, and Lattice Avant devices, alongside new features including RISC-V® variants and improved debug, power calculation, and ease-of-use.
Lattice also announced four solution stack updates in edge AI with Lattice sensAI™, embedded vision with Lattice mVision™, factory automation with Lattice Automate™, and automotive designs with Lattice Drive™. These updates include improved performance with enhanced application-specific features and expanded IP, demo, and reference designs.
These announcements were made today during the livecast at Lattice Developers Conference 2024, a replay of which will soon be available on the event portal site. Lattice Developers Conference is taking place virtually Dec. 10-11, 2024, featuring an incredible lineup of keynotes, breakout sessions, and a robust showcase of FPGA-based technology demonstrations from Lattice and other industry leaders.
For more information on the new products, please read the latest blog and visit:
- Lattice Nexus 2 FPGA platform
- Lattice Certus-N2 FPGA
- Lattice sensAI solution stack
- Lattice mVision solution stack
- Lattice Automate solution stack
- Lattice Drive solution stack
- Lattice Propel
- Lattice Radiant
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210483055/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom